COVID-19 and Cavitary Lesion in Lung.

Cureus

Internal Medicine/Pulmonary Critical Care, Appalachian Regional Healthcare, Harlan, USA.

Published: January 2023

The clinical manifestations of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are widespread, ranging from asymptomatic to critical illness with significant morbidity and mortality. It is widely known that individuals who have viral respiratory infections are more likely to develop bacterial infections. Throughout the pandemic, despite the fact that COVID-19 was thought to be the primary cause of millions of deaths, bacterial coinfections, superinfections, and other secondary complications played a significant role in the increased mortality rate. In our case, a 76-year-old male presented to the hospital complaining of shortness of air. Polymerase chain reaction (PCR) testing was positive for COVID-19 and cavitary lesions were discovered on imaging. Treatment was guided based on the results of bronchoscopy with bronchoalveolar lavage (BAL) cultures showing methicillin-resistant (MRSA) and . However, the case was later complicated by the development of a pulmonary embolism after anticoagulants were held due to new onset hemoptysis. Our case highlights the importance of considering bacterial coinfection in cavitary lung lesions, appropriate antimicrobial stewardship, and close follow-up for full recovery in COVID-19 infections.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946277PMC
http://dx.doi.org/10.7759/cureus.34098DOI Listing

Publication Analysis

Top Keywords

covid-19 cavitary
8
covid-19
4
cavitary lesion
4
lesion lung
4
lung clinical
4
clinical manifestations
4
manifestations coronavirus
4
coronavirus disease
4
disease 2019
4
2019 covid-19 caused
4

Similar Publications

Article Synopsis
  • The study investigates the prevalence of non-COVID-19 lung incidental findings in chest CT scans taken during COVID-19 screenings, specifically focusing on autoimmune conditions related to interstitial lung disease (ILD).
  • It involved a retrospective analysis of 3,000 CT scans performed on adult patients in Al Ain, UAE, between June 2020 and June 2021, that identified 318 patients with lung pathologies beyond typical COVID-19 changes.
  • The results revealed that a significant number (72.6%) had incidental lung nodules, and other pathologies included pleural effusion, bronchiectasis, and a small percentage diagnosed with tuberculosis or cavitary lung lesions.
View Article and Find Full Text PDF
Article Synopsis
  • The study examines the causes and features of pulmonary cavities in patients who have recovered from COVID-19, noting that this condition has increased referrals to a hospital in Tehran.
  • Researchers analyzed medical records of 20 post-COVID-19 patients who developed pulmonary cavities, highlighting data gathered from 2020 to 2021.
  • Findings revealed that 60% of patients had previously been diagnosed with COVID-19, with common additional health issues like type 2 diabetes and bacterial or fungal infections, suggesting that certain risk factors influence the occurrence of pulmonary cavities.
View Article and Find Full Text PDF

We report a rare case of a patient with Janus kinase 2-positive myelofibrosis on ruxolitinib, presenting with indolent pneumonia and cavitary lung lesions. Initial transthoracic biopsy was non-specific, but thoracoscopic biopsy revealed necrotising granulomatous disease caused by pneumonia (PJP). The patient, initially treated with trimethoprim-sulfamethoxazole, was switched to atovaquone due to gastrointestinal intolerance.

View Article and Find Full Text PDF

Objective: To demonstrate clinical features and outcomes in patients with cavitary lung lesions and COVID-19 associated pneumonia.

Material And Methods: A retrospective analysis of electronic medical records of 8261 patients with COVID-19 was performed. We selected 40 patients meeting the inclusion criteria.

View Article and Find Full Text PDF

Background: Coronavirus Disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus type 2, which is characterized by high infectiousness and diverse clinical manifestations. They are more likely to become critical in people who have underlying diseases or are immunocompromised. In the daunting task of treating patients with COVID-19, those with comorbid fungal infections are susceptible to underdiagnosis or misdiagnosis, which can ultimately lead to increased morbidity and mortality in this group of patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!